Saturday, October 08, 2016 3:57:25 PM
The FDA put this company back at least one year maybe two years in last weeks investor presentation update so it will be 2019 before any cash is flowing. The gel is still at best a year out before it will be allowed to be placed into trials. The cervical trial is many months away before it begins. The monthly burn is 1.4 million per month. At this rate all the cash on hand will be used and then another round of financing will be needed which consequently will dilute all shareholders. The executives continue to take handsome bonuses, salaries, and stock options. If they were worth their salt they would be putting out press releases stating the dollar amounts of their money they have invested. The CEO if I am not mistaken was to put up a kings ransom to purchase stock from the open market within the first year of his tenure. This is a great idea but unfortunately a growing disappointment.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM